These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19500018)

  • 21. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.
    Gzyl J; Bolesta E; Wierzbicki A; Kmieciak D; Naito T; Honda M; Komuro K; Kaneko Y; Kozbor D
    Virology; 2004 Jan; 318(2):493-506. PubMed ID: 14972518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine.
    Yan J; Corbitt N; Pankhong P; Shin T; Khan A; Sardesai NY; Weiner DB
    Vaccine; 2011 Sep; 29(41):7173-81. PubMed ID: 21651948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
    Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.
    Zurawski G; Zurawski S; Flamar AL; Richert L; Wagner R; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Bonnabau H; Klucar P; Wang Z; Foulds KE; Kao SF; Yates NL; LaBranche C; Jacobs BL; Kibler K; Asbach B; Kliche A; Salazar A; Reed S; Self S; Gottardo R; Galmin L; Weiss D; Cristillo A; Thiebaut R; Pantaleo G; Levy Y
    PLoS One; 2016; 11(4):e0153484. PubMed ID: 27077384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env.
    Collado M; Rodríguez D; Rodríguez JR; Vázquez I; Gonzalo RM; Esteban M
    Vaccine; 2000 Jul; 18(27):3123-33. PubMed ID: 10856792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
    Ching L; Stamatatos L
    J Virol; 2010 Oct; 84(19):9932-46. PubMed ID: 20660181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.
    Xu J; Ren L; Huang X; Qiu C; Liu Y; Liu Y; Shao Y
    AIDS; 2006 Nov; 20(18):2293-303. PubMed ID: 17117015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A novel immunization strategy to induce strong humoral responses against HIV-1 using combined DNA, recombinant vaccinia virus and protein vaccines].
    Liu C; Wang SH; Ren L; Hao YL; Zhang QC; Liu Y
    Bing Du Xue Bao; 2014 Nov; 30(6):645-51. PubMed ID: 25868279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of immune responses to an HIV env DNA vaccine by a C-terminal segment of listeriolysin O.
    Bu Z; Ye L; Skeen MJ; Ziegler HK; Compans RW; Yang C
    AIDS Res Hum Retroviruses; 2003 May; 19(5):409-20. PubMed ID: 12803999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.
    Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM
    Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.
    Weaver EA; Lu Z; Camacho ZT; Moukdar F; Liao HX; Ma BJ; Muldoon M; Theiler J; Nabel GJ; Letvin NL; Korber BT; Hahn BH; Haynes BF; Gao F
    J Virol; 2006 Jul; 80(14):6745-56. PubMed ID: 16809280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.
    Cram JA; Fiore-Gartland AJ; Srinivasan S; Karuna S; Pantaleo G; Tomaras GD; Fredricks DN; Kublin JG
    PLoS One; 2019; 14(12):e0225622. PubMed ID: 31869338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
    Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.
    Beck Z; Matyas GR; Jalah R; Rao M; Polonis VR; Alving CR
    Vaccine; 2015 Oct; 33(42):5578-5587. PubMed ID: 26372857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
    Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
    Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.